Consensus of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH) and the Brazilian Ministry of Health - General management of blood and blood products on the tests necessary for the release of exceptional medicines for sickle cell disease
Hematol., Transfus. Cell Ther. (Impr.)
;
46(1): 67-71, Jan.-Mar. 2024.
Article
Dans Anglais
|
LILACS-Express
| LILACS
| ID: biblio-1557881
ABSTRACT
Abstract To date, hydroxyurea is the only effective and safe drug that significantly reduces morbidity and mortality of individuals with Sickle cell disease. Twenty years of real-life experience has demonstrated that hydroxyurea reduces pain attacks, vaso-occlusive events, including acute chest syndrome, the number and duration of hospitalizations and the need for transfusion. The therapeutic success of hydroxyurea is directly linked to access to the drug, the dose used and adherence to treatment which, in part, is correlated to the availability of hydroxyurea. This consensus aims to reduce the number of mandatory exams needed to access the drug, prioritizing the requesting physician's report, without affecting patient safety.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Pays comme sujet:
Amérique du Sud
/
Brésil
langue:
Anglais
Texte intégral:
Hematol., Transfus. Cell Ther. (Impr.)
Thème du journal:
Hematologia
/
TransfusÆo de Sangue
Année:
2024
Type:
Article
Pays d'affiliation:
Brésil
/
États-Unis d'Amérique
Institution/Pays d'affiliation:
Centro Municipal de Saúde Leonidia Ayres Barreiras/BR
/
Centro de referência em doença falciforme de Itabuna/BR
/
Fundação Hemocentro de Rondônia/BR
/
Fundação Hemominas/BR
/
Fundação de Hematologia e Hemoterapia de Pernambuco/BR
/
Fundação de Hematologia e Hemoterapia do Amazonas/BR
/
Grupo GSH/BR
/
HEMOPAC/BR
/
Hemocentro Coordenador do Estado do Rio de Janeiro/BR
/
Hemocentro de Goiânia/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS